Previous 10 | Next 10 |
2024-02-07 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Accolade Welcomes Kindbody to Trusted Partner Ecosystem PR Newswire Kindbody partnership builds on Accolade's commitment to offer best-in-class women's health, fertility and family-forming capabilities for customers and members SEATTLE , Jan. 23, 2024 /PR...
2024-01-19 06:45:01 ET Wells Fargo analyst issues BUY recommendation for ACCD on January 19, 2024 07:01AM ET. The previous analyst recommendation was Buy. ACCD was trading at $11.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
2024-01-17 03:23:06 ET Summary I continue to recommend a buy rating with a projected 20% growth in FY25. Recent results show that Accolade beat consensus estimates for revenue and EBITDA, and management expects 20% revenue growth and 2-4% EBITDA margins in FY25. Tailwinds for ...
2024-01-10 23:01:55 ET Summary ACCD's Q3 FY 2024 top line and non-GAAP adjusted EBITDA loss came in better than the Wall Street analysts had anticipated. Accolade also revised its FY 2024 revenue outlook upwards, and shared its updated expectations of a narrower EBITDA loss for th...
2024-01-09 19:36:03 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; NexImmune Inc (NASDAQ: NEXI), Adicet Bio Inc (NASDAQ: ACET), Cellectar Biosciences Stock (NASDAQ: CLRB), and Accolade (NASDAQ: ACCD). Other than ...
2024-01-09 12:40:00 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cutera Inc (NASDAQ: CUTR), Sentage Holdings (NASDAQ: SNTG), NexImmune Inc (NASDAQ: NEXI), Adicet Bio In...
2024-01-08 19:20:24 ET Accolade, Inc. (ACCD) Q3 2024 Earnings Call Transcript January 08, 2024, 04:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Conference Call Participants Ryan Daniels - Blair Craig ...
2024-01-08 16:07:34 ET More on Accolade Accolade: Multiples Should Rerate As ACCD Continues To Execute Accolade Q3 2024 Earnings Preview Accolade announces repurchase of $76.5M of 0.50% convertible senior notes due 2026 Seeking Alpha’s Quant Rating on ...
SEATTLE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal third quarter ended November 30, 2023. “As we head into the new year, Accolade continues to define the future of how healthcare should be experienced in this...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...